Genomes and Genes
Summary: Compounds which inhibit or antagonize the biosynthesis or actions of aldosterone.
Publications203 found, 100 shown here
- Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation StudyDavid N Juurlink
Department of Medicine University of Toronto, Toronto
N Engl J Med 351:543-51. 2004..Use of angiotensin-converting-enzyme (ACE) inhibitors is also indicated in these patients. However, life-threatening hyperkalemia can occur when these drugs are used together...
- Potassium homeostasis and renin-angiotensin-aldosterone system inhibitorsMatthew R Weir
Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, 22 South Greene Street, Room N3W143, Baltimore, MD 21201, USA
Clin J Am Soc Nephrol 5:531-48. 2010..Moreover, these patients are likely to derive benefit from RAAS inhibition. Rather than denying them an effective treatment, electrolyte levels should be closely monitored in these patients...
- Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blockerMiki Nagase
Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Hypertension 47:1084-93. 2006....
- Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertensionMyron H Weinberger
Indiana University School of Medicine, Hypertension Research Center, Indianapolis 46202 5111, USA
Am J Hypertens 15:709-16. 2002..Eplerenone, a selective aldosterone blocker (SAB) that is highly specific for the aldosterone receptor, has the potential to be efficacious in the treatment of hypertension...
- Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy studyBertram Pitt
University of Michigan Health System, Ann Arbor, Mich, USA
Circulation 108:1831-8. 2003..This study compared LVH regression during treatment with the selective aldosterone blocker eplerenone, enalapril, and their combination in patients with hypertension...
- Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndromeRobert W Schrier
Department of Medicine, University of Colorado Denver, Division of Renal Diseases and Hypertension, Aurora, CO 80045, USA
Clin J Am Soc Nephrol 5:1132-40. 2010..The effect of aldosterone in metabolic syndrome is also discussed in this review...
- Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiolIngrid J M Duijkers
Dinox, Groningen, The Netherlands
Eur J Contracept Reprod Health Care 15:314-25. 2010..To compare the effects on ovarian activity of two oral contraceptives containing nomegestrol acetate (NOMAC)/17 beta-oestradiol (E2) or drospirenone (DRSP)/ethinylestradiol (EE)...
- Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blockerYoshiyuki Furumatsu
Department of Kidney Disease and Hypertension, Osaka General Medical Center, Japan
Hypertens Res 31:59-67. 2008..In conclusion, triple blockade of the RAAS was effective for the treatment of proteinuria in patients with non-diabetic nephropathy whose increased urinary protein had not responded sufficiently to a dual blockade...
- The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observationJürgen C Dinger
Center for Epidemiology and Health Research ZEG, 10115 Berlin, Germany
Contraception 75:344-54. 2007..The study was conducted to compare risks of adverse cardiovascular and other events associated with the use of drospirenone (DRSP)-containing oral contraceptives (OCs) and other OCs...
- Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronismAsterios Karagiannis
Aristotle University of Thessaloniki, Second Propedeutic Department of Internal Medicine, Medical School, Hippokration Hospital, Thessaloniki, Greece
Expert Opin Pharmacother 9:509-15. 2008..It was concluded that eplerenone was as effective as spironolactone in reducing BP in patients with IHA. The risk of mild hyperkalaemia was similar with both drugs...
- Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathyUzma F Mehdi
University of Texas Southwestern Medical Center, 5939 Harry Hines Boulevard, Dallas, TX 75930, USA
J Am Soc Nephrol 20:2641-50. 2009..These results support the need to conduct a long-term, large-scale, renal failure outcomes trial...
- Eplerenone in patients with systolic heart failure and mild symptomsFaiez Zannad
INSERM, Centre d Investigation Clinique 9501 and Unité 961, and the Department of Cardiology, Nancy University, Nancy, France
N Engl J Med 364:11-21. 2011..We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms...
- Cardiac aldosterone production in genetically hypertensive ratsY Takeda
Second Department of Internal Medicine, Department of Health Sciences, School of Medicine, Kanazawa University, Kanazawa, Japan
Hypertension 36:495-500. 2000..These results suggest that the rat heart produces aldosterone and that endogenous cardiac aldosterone may affect cardiac function and hypertrophy in hypertension in rats...
- Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot studyStefano Bianchi
, Spedali Riuniti di Livorno, Livorno, Italy
Am J Kidney Dis 46:45-51. 2005..Concerns remain in regard to the risk for hyperkalemia in patients with CKD. Prospective randomized trials are necessary to confirm the efficacy and safety of antagonists of aldosterone on proteinuria and progression of CKD...
- Effects of eplerenone versus losartan in patients with low-renin hypertensionMyron H Weinberger
Hypertension Research Center, Indiana University School of Medicine, Indianapolis, IN 46202 5111, USA
Am Heart J 150:426-33. 2005..Agents that block aldosterone at its receptor sites, therefore, should have significant clinical benefit in patients with low-renin hypertension...
- Effect of spironolactone on blood pressure in subjects with resistant hypertensionNeil Chapman
International Centre for Circulatory Health, Imperial College London, 59 North Wharf Rd, London W2 1PG, United Kingdom
Hypertension 49:839-45. 2007..Although nonrandomized and not placebo controlled, these data support the use of spironolactone in uncontrolled hypertension...
- Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarctionCarmem Luíza Sartório
Medizinische Klinik und Poliklinik I, Universitatsklinikum Wurzburg, Bayerische Julius Maximilians Universität Würzburg, Germany
Hypertension 50:919-25. 2007..Underlying mechanisms involve inhibition of vascular angiotensin-converting enzyme upregulation and improvement of endothelial NO synthase-derived NO bioavailability...
- Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trialsJustin A Ezekowitz
Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada
Eur Heart J 30:469-77. 2009..Aldosterone blockade has been used to treat acute myocardial infarction (MI) and chronic heart failure...
- Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonismRosana Poggio
Heart Failure and Heart Transplant Program, Department of Cardiology, FLENI, Buenos Aires, Argentina
Postgrad Med J 86:136-42. 2010..of angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and aldosterone antagonists. High potassium concentrations in heart failure could lead to life threatening events, and therefore ..
- A comparison of the aldosterone-blocking agents eplerenone and spironolactoneAllan Struthers
Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, Dundee, UK
Clin Cardiol 31:153-8. 2008..Choice of a specific agent should be based on individual patient issues, such as the nature of heart failure and patient concerns about adverse events...
- Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelinesBiykem Bozkurt
Winters Center for Heart Failure Research, VA Medical Center, Baylor College of Medicine, Houston, Texas, USA
J Am Coll Cardiol 41:211-4. 2003..Clinical follow-up does not adhere to the RALES trial guidelines, resulting in higher complications. We conclude that long-term studies with further safety and efficacy data are needed...
- Low-dose spironolactone in the management of resistant hypertension: a surveillance studyDeirdre A Lane
University Department of Medicine, City Hospital, Birmingham, UK
J Hypertens 25:891-4. 2007..This drug was recommended in 133 patients who were already receiving an angiotensin-blocking drug in addition to other therapies...
- Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysisSankar D Navaneethan
Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio 44195, USA
Clin J Am Soc Nephrol 4:542-51. 2009Addition of aldosterone antagonists (AA) might provide renal benefits to proteinuric chronic kidney disease (CKD) patients over and above the inhibition of renin-angiotensin system blockers (RAS)...
- Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetesMurray Epstein
University of Miami School of Medicine, Miami, Florida, USA
Clin J Am Soc Nephrol 1:940-51. 2006..Co-administration of EPL50 or EPL100 with an ACE inhibitor as compared with an ACE inhibitor alone significantly reduces albuminuria in patients with diabetes without producing significant increases in hyperkalemia...
- Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal diseaseAtsuhisa Sato
Department of Internal Medicine, Mito Red Cross Hospital, Ibaraki, Japan
Am J Hypertens 18:44-9. 2005..Additional, larger, prospective, randomized double-blind studies will be needed for general acceptance of this strategy...
- Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathologyJennifer L Wilkinson-Berka
Department of Immunology, Monash University, Commercial Rd, Prahran, Victoria, Australia, 3004
Circ Res 104:124-33. 2009..We make the first report that MR and aldosterone influence retinal vasculopathy, which may involve inflammatory and G6PD mechanisms. MR antagonism may be relevant when developing treatments for retinopathies that target the RAAS...
- Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in ratsJun Du
Department of Pharmacology, Kagawa University Medical School, Kagawa, Japan
Am J Physiol Renal Physiol 297:F802-8. 2009..The combination of eplerenone and amlodipine improved renal injury more effectively than either monotherapy in high salt-fed DS rats, presumably by achieving their own renoprotective effects...
- Aldosterone target organ protection by eplerenoneAmy E Rudolph
Pharmacia Corporation, Cardiovascular and Metabolic Diseases, 800 N Lindbergh Blvd, T1G T108W, St Louis, MO 63167, USA
Mol Cell Endocrinol 217:229-38. 2004....
- Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trialLeszek Tylicki
Department of Nephrology Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland
Am J Kidney Dis 52:486-93. 2008....
- Beneficial impact of spironolactone in diabetic nephropathyKatrine Jordan Schjoedt
Steno Diabetes Center, Gentofte, Denmark
Kidney Int 68:2829-36. 2005..We therefore aimed to evaluate the short-term effect of aldosterone antagonism with spironolactone on albuminuria and blood pressure in diabetic nephropathy...
- Rapid non-genomic vasoconstrictor actions of aldosterone in the renal microcirculationShuji Arima
Department of Vascular and Geriatric Medicine, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama 589 8511, Japan
J Steroid Biochem Mol Biol 102:170-4. 2006..Thus, in addition to genomic actions, such non-genomic vasoconstrictor actions in the renal microcirculation may contribute to the deleterious renal effects of aldosterone in renal diseases...
- Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactonePaul Mulder
Faculte de Medecine et Pharmacie, INSERM U644, 22 Boulevard Gambetta, 76183 Rouen Cedex, France
Eur Heart J 29:2171-9. 2008..Inhibition of aldosterone synthase, the key enzyme in aldosterone formation, could be an alternative strategy for mineralocorticoid-receptor antagonists in congestive heart failure (CHF), but its effect in CHF is unknown...
- Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high saltWilliam B Lea
Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
Kidney Int 75:936-44. 2009..Our study shows that mineralocorticoid receptor antagonism and aldosterone synthase inhibition similarly decrease hypertrophy and interstitial fibrosis of the kidney and heart caused by angiotensin II and high salt...
- Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive ratsBing S Huang
University of Ottawa Heart Institute, Ottawa, ON, Canada K1Y 4W7
Am J Physiol Regul Integr Comp Physiol 296:R994-R1000. 2009..These results suggest that, in Dahl S rats, high salt intake increases aldosterone synthesis in the hypothalamus and aldosterone acts as the main MR agonist activating central pathways contributing to salt-induced hypertension...
- Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001Frederick A Masoudi
Division of Cardiology, Department of Medicine, Denver Health Medical Center, Denver, CO 80204, USA
Circulation 112:39-47. 2005..We studied the adoption of spironolactone therapy after publication of the Randomized Aldactone Evaluation Study (RALES) in national cohorts of older patients hospitalized for heart failure...
- High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarctionFarzin Beygui
Cardiology Department and INSERM U 856, , Paris, France
Circulation 114:2604-10. 2006..Such results underline the pivotal role of aldosterone and justify a randomized trial to assess the early administration of aldosterone antagonists in the setting of STEMI.
- Spironolactone improves diastolic function in the elderlyChanwit Roongsritong
Division of Cardiology, Texas Tech University Health Sciences Center, Lubbock, TX 79430 9410, USA
Clin Cardiol 28:484-7. 2005..Increased myocardial fibrosis, a major determinant of diastolic function, has been observed with advancing age. Spironolactone prevents age-related increases in myocardial fibrosis in old normotensive rats...
- Long-term effect of spironolactone on cardiac structure as assessed by analysis of ultrasonic radio-frequency signals in patients with ventricular hypertrophyNagahiro Nishikawa
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, Japan
Circ J 69:1394-400. 2005..Aldosterone blockade may alter myocardial ultrasonic texture with regression of LV fibrosis, at least partly through enhanced collagen degradation...
- Aldosterone antagonists in the treatment of heart failureTodd R Marcy
University of Oklahoma College of Pharmacy, Oklahoma City, OK 73190, USA
Am J Health Syst Pharm 63:49-58. 2006The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart failure are reviewed.
- Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final resultsAlessandro Boccanelli
Department of Cardiovascular Diseases, San Giovanni Addolorata Hospital, Roma, Italy
Eur J Heart Fail 11:68-76. 2009..Aldosterone receptor antagonists improve outcome in severe HF, but no information is available in NYHA class II...
- Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunctionJames E Udelson
Tufts Medical Center, 750 Washington Street, Boston, MA 02111, USA
Circ Heart Fail 3:347-53. 2010..Few data are available on effects of aldosterone antagonism in patients with mild-to-moderate HF...
- Use of aldosterone antagonists in heart failureNancy M Albert
Nursing Institute and Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio, USA
JAMA 302:1658-65. 2009b>Aldosterone antagonists are recommended for patients with moderate to severe heart failure (HF) and systolic dysfunction...
- Induction of cardiac fibrosis by aldosteroneP Lijnen
Department of Molecular and Cardiovascular Research, Faculty of Medicine, University of Leuven, Belgium
J Mol Cell Cardiol 32:865-79. 2000....
- Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney diseaseRichard A Preston
Division of Clinical Pharmacology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
Hypertension 53:754-60. 2009....
- Rationale for the use of aldosterone antagonists in congestive heart failureRicardo Rocha
Division of Cardiovascular and Metabolic Diseases, Pharmacia Corp, Skokie, Illinois, USA
Drugs 62:723-31. 2002..These findings suggest the dissociation between cardiovascular lesions and high blood pressure, and highlight the importance of aldosterone in the pathological changes...
- Safety of spironolactone use in ambulatory heart failure patientsRicardo J Lopes
Department of Cardiology, Hospital São João 4200 319 Porto, Portugal
Clin Cardiol 31:509-13. 2008..There is limited information on the use, side effects, and withdrawal rate of spironolactone in routine clinical practice...
- Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failureLarisa H Cavallari
Department of Pharmacy Practice, University of Illinois at Chicago, 60612 7230, USA
Pharmacotherapy 30:1-9. 2010..To identify patient-specific factors associated with spironolactone-induced potassium level elevation in patients with heart failure...
- Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF)Faiez Zannad
INSERM, Centre d Investigation Cliniques CIC 9501 and U961, CHU and Department of Cardiology, Nancy University, Nancy, France
Eur J Heart Fail 12:617-22. 2010In chronic heart failure (HF), aldosterone antagonists have been shown to improve survival in patients with low ejection fraction and moderate-to-severe symptoms [New York Heart Association (NYHA) classes III and IV]...
- Aldosterone antagonist improves diastolic function in essential hypertensionAnna M Grandi
Department of Clinical and Biological Sciences, University of Insubria, Varese, Italy
Hypertension 40:647-52. 2002..This improvement, not accounted for by changes in blood pressure and left ventricular mass, can be therefore ascribed to a direct action of the drug on the myocardium...
- Mineralocorticoid receptor antagonists and endothelial functionBradley A Maron
Harvard Medical School, Brigham and Women s Hospital, Department of Medicine, Cardiovascular Division, 77 Avenue Louis Pasteur, NRB 0630K, Boston, MA 02115, USA
Curr Opin Investig Drugs 9:963-9. 2008..Therefore, the development of newer agents with more favorable side-effect profiles is needed...
- Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarctionBertram Pitt
University of Michigan, Ann Arbor, USA
N Engl J Med 348:1309-21. 2003....
- How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?Morten Svensson
Frederiksberg University Hospital, Department of Cardiology and Endocrinology Frederiksberg Copenhagen, Denmark
J Card Fail 10:297-303. 2004....
- Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control studyJürgen Dinger
Director, ZEG Berlin Center for Epidemiology and Health Research, Invalidenstrasse 115, 10115 Berlin, Germany
J Fam Plann Reprod Health Care 36:123-9. 2010..The secondary objective was to investigate the VTE risk associated with drospirenone/ethinylestradiol (DRSP/EE) in comparison to low-dose LNG/EE...
- Spironolactone use and renal toxicity: population based longitudinal analysisLi Wei
Medicines Monitoring Unit MEMO, Division of Medical Sciences, Ninewells Hospital and Medical School, Dundee DD1 9SY
BMJ 340:c1768. 2010..To determine the safety of spironolactone prescribing in the setting of the UK National Health Service...
- Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesionMassimiliano Caprio
Department of Medicine Division of Cardiology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
Circ Res 102:1359-67. 2008In clinical trials, aldosterone antagonists decrease cardiovascular mortality and ischemia by unknown mechanisms...
- Eplerenone: cardiovascular protectionNancy J Brown
Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn 37232 6602, USA
Circulation 107:2512-8. 2003..This review provides an overview of the pharmacology, efficacy, and safety of a new, more selective aldosterone receptor antagonist, eplerenone, in the context of emerging concepts of the role of aldosterone in cardiovascular toxicity...
- The role of aldosterone antagonists in the management of resistant hypertensionMari K Nishizaka
Vascular Biology and Hypertension Program, University of Alabama at Birmingham, 430 BMR2, 1530 3rd Avenue South, Birmingham, AL 35294-2180, USA
Curr Hypertens Rep 7:343-7. 2005..Recent studies indicate that aldosterone antagonists provide significant blood pressure reduction when added to antihypertensive regimens of patients with ..
- Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertensionWilliam B White
Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
Circulation 112:1979-84. 2005..In prior studies with DRSP in postmenopausal women that were focused on relief of menopausal symptoms, DRSP/E2 yielded significant reductions in blood pressure (BP)...
- Drospirenone, a new progestogen, for postmenopausal women with hypertensionMadhavi Mallareddy
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
Drugs Aging 24:453-66. 2007..Thus, drospirenone is a unique progestogen that confers the additional benefit of BP reduction, an effect that could lead to potential benefit with respect to some cardiovascular risk concerns in women taking hormone therapy...
- Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammationHylton V Joffe
Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Ave, Boston, MA 02115, USA
Heart Fail Rev 10:31-7. 2005..This review focuses on the adverse effects of aldosterone on the vascular system and describes our current understanding of the underlying mechanisms for this injury...
- Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practiceJohn McMurray
Department of Cardiology, Western Infirmary, Glasgow, G12 8QQ, UK
Eur J Heart Fail 7:710-21. 2005..Recent trials have now shown that treatment with beta-blockers, aldosterone antagonists and angiotensin receptor blockers also leads to substantial improvements in outcome...
- Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptomsO Ylikorkala
Climacteric 8:1-3. 2005
- Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular diseaseRichard N Re
Research Division, Ochsner Clinic Foundation, New Orleans, LA 70121, USA
Nat Clin Pract Cardiovasc Med 1:42-7. 2004....
- Drospirenone and its antialdosterone propertiesA R Genazzani
Department of Obstetrics and Gynecology, University of Pisa, Pisa, Italy
Climacteric 10:11-8. 2007..The combined actions of drospirenone on sodium and water retention and cardiovascular parameters make it a more attractive therapeutic option as a component of hormone replacement therapy than other synthetic progestins...
- Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activityJane A Leopold
Whitaker Cardiovascular Institute, 700 Albany Street, Boston University School of Medicine, Boston, Massachusetts 02118, USA
Nat Med 13:189-97. 2007..These findings demonstrate that aldosterone induces a G6PD-deficient phenotype to impair endothelial function; aldosterone antagonism or gene transfer of G6pd improves vascular reactivity by restoring G6PD activity...
- Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1Shigeru Shibata
Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
Hypertension 49:355-64. 2007..Aldosterone can directly modulate podocyte function, possibly through the induction of oxidative stress and Sgk1...
- Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertensionKrishna K Gaddam
Vascular Biology and Hypertension Program, University of Alabama at Birmingham, 115 Community Health Services Building, 933 19 Street South, Birmingham, AL 35294, USA
Expert Rev Cardiovasc Ther 4:353-9. 2006..Recent clinical studies indicate that aldosterone antagonists provide significant additional blood pressure reduction when added to treatment regimens of patients with ..
- Use of aldosterone antagonists in resistant hypertensionDavid A Calhoun
Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, AL, USA
Prog Cardiovasc Dis 48:387-96. 2006..Recent clinical studies indicate that aldosterone antagonists, spironolactone and amiloride, provide significant additional blood pressure reduction when added to ..
- Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinasShigefumi Nakano
Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Shimotsuga-gun, Tochigi 321-0293, Japan
Hypertens Res 28:925-36. 2005..Spironolactone may be useful as a cardioprotective agent to prevent cardiovascular remodeling via the ACE/EGFR/ERK, NAD(P)H oxidase/LOX-1, and Rho-kinase pathways...
- Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trialDavid F Archer
CONRAD Clinical Research Center, 601 Colley Avenue, Norfolk, VA 23507, USA
Menopause 12:716-27. 2005....
- Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter studyB S Lee
Department of Obstetrics and Gynecology, College of Medicine, Yonsei University, Seoul, Republic of Korea
Maturitas 57:361-9. 2007....
- Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot studyHideo Izawa
Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya 466 8550, Japan
Circulation 112:2940-5. 2005....
- Aldosterone blockade: an emerging strategy for abrogating progressive renal diseaseMurray Epstein
Department of Medicine, University of Miami School of Medicine, Miami, Fla, USA
Am J Med 119:912-9. 2006....
- Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivoN J Brown
Departments of Medicine and Pharmacology, Pathology, and Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Kidney Int 58:1219-27. 2000....
- Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatmentJ E Macdonald
Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Dundee DD19SY, UK
Heart 90:765-70. 2004....
- Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstructionHoward Trachtman
Department of Pediatrics, Schneider Children s Hospital, New Hyde Park, New York 11040, USA
J Urol 172:1590-4. 2004..We conducted experiments to determine whether administration of spironolactone, a mineralocorticoid receptor antagonist, reduced renal fibrosis in an experimental model of obstructive uropathy...
- Spironolactone prevents early renal injury in streptozotocin-induced diabetic ratsGenro Fujisawa
Divisions of Endocrinology, Department of Internal Medicine, Jichi Medical School, Minamikawachi, Tochigi, Japan
Kidney Int 66:1493-502. 2004..The present study investigated whether and how mineralocorticoid receptor antagonist spironolactone ameliorates early renal injury in streptozotocin-induced diabetic rats...
- Aldosterone-induced vasculopathyAllan D Struthers
Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, UK
Mol Cell Endocrinol 217:239-41. 2004b>Aldosterone antagonists reduce mortality in chronic heart failure (CHF). An obvious question to ask is how do they do this...
- Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytesLorenzo A Calo
Department of Clinical and Experimental Medicine, Clinica Medica 4, University of Padua, Padua 35100, Italy
J Clin Endocrinol Metab 89:1973-6. 2004..In addition, the results confirm our previous data on a direct effect of glycyrrhetinic acid at the level of mineralocorticoid receptors...
- Rapid effects of aldosterone on vascular cells: clinical implicationsRalf Losel
Department of Clinical Pharmacology Mannheim, Institut fur Klinische Pharmakologie, University of Heidelberg, Klinikum Mannheim, Theodor Kutzer Ufer, D 68167 Mannheim, Germany
Steroids 69:575-8. 2004..As many rapid and thus nonclassic aldosterone responses cannot be blocked by spironolactone, further research is required in order to provide adequate inhibitors to interfere with these pathways...
- Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic ratsG Miric
Department of Physiology and Pharmacology, School of Biomedical Sciences, The University of Queensland, Australia
Br J Pharmacol 133:687-94. 2001..Thus, short-term pirfenidone and spironolactone treatment reversed cardiac and renal fibrosis and attenuated the increased diastolic stiffness without normalizing cardiac contractility or renal function in STZ-diabetic rats...
- Aldosterone-induced inflammation in the rat heart : role of oxidative stressYao Sun
Department of Medicine, Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Memphis 38163, USA
Am J Pathol 161:1773-81. 2002..Spionolactone, PDTC, and NAC each attenuated these responses suggesting ALDO/salt induction of oxidative/nitrosative stress is responsible for the appearance of this proinflammatory phenotype...
- Review of aldosterone- and angiotensin II-induced target organ damage and preventionAllan D Struthers
Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Tayside DD1 9SY, Dundee, UK
Cardiovasc Res 61:663-70. 2004....
- Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failureNimit C Shah
Department of Medicine and Therapeutics, Ninewells Hospital, Dundee, UK
J Renin Angiotensin Aldosterone Syst 7:20-30. 2006..Finally, aldosterone blockade has been shown to reduce atherosclerosis in animal studies of atherosclerosis without heart failure, which are analogous to CAD patients...
- Hypertension, angiotensin II, aldosterone, and raceOri Ben-Yehuda
J Am Coll Cardiol 41:1156-8. 2003
- Aldosterone antagonists: the most underutilized class of heart failure medicationsMaya Guglin
Wayne State University, Detroit, Michigan 48201, USA
Am J Cardiovasc Drugs 7:75-9. 2007b>Aldosterone antagonists have been proven to be beneficial in severe heart failure (HF) as a result of systolic dysfunction...
- Aldosterone receptor antagonists for heart failure: current status, future indicationsBertram Pitt
University of Michigan School of Medicine, Ann Arbor, MI, USA
Cleve Clin J Med 73:257-60, 264-8. 2006..We review the evidence and indications...
- The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failureZhi-Hua Zhang
Department of Internal Medicine and Cardiovascular Center, University of Iowa, Iowa City, 52242, USA
Am J Physiol Heart Circ Physiol 283:H423-33. 2002..This mechanism of neurohumoral excitation in HF is accessible to manipulation by blood-borne therapeutic agents...
- [Aldosterone receptor blockade after acute myocardial infarction with heart failure]Johann Bauersachs
Medizinische Klinik I, Universitatsklinikum, Josef Schneider Strasse 2, 97080 Wurzburg
Med Klin (Munich) 101:458-66. 2006..basis, the experimental and clinical trials that constitute the rationale for therapy with aldosterone antagonists in patients with acute myocardial infarction and heart failure...
- Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidneyMaristela Lika Onozato
Division of Nephrology and Endocrinology, Department of Internal Medicine, University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
Nephrol Dial Transplant 22:1314-22. 2007....
- Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failureTera D Moore
South Texas Veterans Health Care System, San Antonio, TX, USA
Heart Dis 5:354-63. 2003..have been documented in patients with hypertension and heart failure, leading to the use of aldosterone antagonists for the treatment of these conditions...
- Adherence to guidelines for patients hospitalized with heart failure: a nationwide surveyAlan B Jotkowitz
Department of Internal Medicine F, Soroka Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
Isr Med Assoc J 8:875-9. 2006..Despite significant advances in the therapy of heart failure, many patients still do not receive optimal treatment...
- Primary hyperaldosteronism in a patient with end-stage renal diseaseAmir Kazory
Division of Nephrology, University of Florida, 1600 SW Archer Rd, Gainesville, FL 32610, USA
Nephrol Dial Transplant 22:917-9. 2007
- Treatment of polycystic ovary syndrome with spironolactone plus licoriceDecio Armanini
Department of Medical and Surgical Sciences Endocrinology, University of Padua, Padua, Italy
Eur J Obstet Gynecol Reprod Biol 131:61-7. 2007....
- Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failureAtsushi Kambara
Division of Cardiothoracic Surgery, The Ohio State University, Columbus, Ohio 43210, U S A
J Cardiovasc Pharmacol 41:830-7. 2003..These data suggest that the addition of low-dose SPIRO to angiotensin I-converting enzyme inhibitor treatment may prevent progression into end-stage congestive heart failure through synergistic effects on diuresis and renoprotection...
- Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failureFrederick A Masoudi
Division of Cardiology, Denver Health Medical Center, Denver, Colo 80204, USA
Am Heart J 146:250-7. 2003..Our objective was to determine the proportion of older persons meeting enrollment criteria of randomized controlled trials of agents that prolong life in heart failure...
- Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patientsJohn M Flack
Department of Internal Medicine, Wayne State University, Detroit, Michigan 48201, USA
J Am Coll Cardiol 41:1148-55. 2003..The purpose of this study was to evaluate the efficacy and tolerability of monotherapy with the selective aldosterone blocker eplerenone in both black and white patients with hypertension...
- Eplerenone, a new selective aldosterone blockerEllen G McMahon
Mail Zone T1G, Pharmacia Corporation, 800 North Lindbergh Blvd, St Louis, Missouri 63167, USA
Curr Pharm Des 9:1065-75. 2003..Early clinical studies suggests that eplerenone may have important therapeutic benefit in the treatment of hypertension and heart failure post-myocardial infarction (post-MI)...
- Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humansPairunyar Sawathiparnich
Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
J Clin Endocrinol Metab 87:448-52. 2002..57; P = 0.0003); however, treatment with spironolactone abolished this correlation (r(2) = 0.13; P = 0.33). This study provides evidence that endogenous aldosterone influences PAI-1 production in humans...
- Aldosterone as a mediator in cardiovascular injuryCharles T Stier
Department of Pharmacology, New York Medical College, Valhalla, New York 10595, USA
Cardiol Rev 10:97-107. 2002..The advent of selective aldosterone receptor antagonists such as eplerenone should prove of great therapeutic value in the prevention of cardiovascular disease and associated end-organ damage...
- [Aldosterone blockade in heart failure. So much for so little]José R González-Juanatey
Med Clin (Barc) 118:779-81. 2002
Research Grants122 found, 100 shown here
- Etiology of Sleep Apnea-Related HyperaldosteronismDavid A Calhoun; Fiscal Year: 2010..Both possibilities would significantly lower cardiovascular risk in patients with difficult-to-control hypertension. ..
- Etiology of Sleep Apnea-Related HyperaldosteronismDavid Calhoun; Fiscal Year: 2007..Subjects found not to have OSA will serve as controls. ..
- ACTION - A CHF Trial Investigating Outcomes of ExerciseGregg Fonarow; Fiscal Year: 2006..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
- HEART FAILURE & NORMAL SYSTOLIC FUNCTION IN OLDER ADULTSFrederick Masoudi; Fiscal Year: 2004..abstract_text> ..
- PREVENTION OF STROKE DYSFUNCTION BY ACE INHIBITIONCHARLES STIER; Fiscal Year: 2003..abstract_text> ..
- Diabetes and Drug-Associated Hyperkalemia: Effect of Laboratory MonitoringMarsha Raebel; Fiscal Year: 2007..The findings will also assist in developing a framework for future studies to evaluate the effects and costs of medication-laboratory monitoring among patients with diabetes. ..
- PREVENTION OF STROKE & KIDNEY DYSFUNCTIONCHARLES STIER; Fiscal Year: 1991..Stroke is currently the nation's third largest killer (over 150,000 Americans/year). Our studies will provide important information in an area relevant to the therapy of hypertension, kidney dysfunction and stroke...
- DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORSDavid Archer; Fiscal Year: 2006..If successful, DOX treatment could become an important adjuvant for treatment of this and possibly other inflammatory disorders effecting reproductive tract tissues. ..
- Improving Outcomes in Diabetic NephropathyRobert Toto; Fiscal Year: 2005..abstract_text> ..
- Renin-angiotensin and fibrinolysis interaction in humansNancy Brown; Fiscal Year: 2005..It is anticipated that these studies will generate critical new information regarding the mechanisms through which the RAA and kallikrein-kinin systems regulate vascular fibrinolytic function. ..
- Pharmacogenetics of ACE inhibitor-associated angioedemaNANCY JOAN BROWN; Fiscal Year: 2010..Understanding how ACE inhibitors and DPPIV inhibitors interact will help physicians prescribe these medications safely and will influence the development of new medications to treat diabetes and high blood pressure. ..
- Contingency Management for Initiating Smoking AbstinenceWILLIAM BARRY WHITE; Fiscal Year: 2010..Clinic and 24-hour blood pressure (BP) and heart rate (HR) will be additional outcomes. We expect that BP and HR will decrease more among CM than non-CM patients and reductions in smoking may mediate decreases in these indices. ..
- Renin-angiotensin and fibrinolysis interaction in humansNancy Brown; Fiscal Year: 2009..These studies promise to yield novel pharmacological strategies to decrease the prevalence of diabetes and mortality due to thrombotic cardiovascular events in the metabolic syndrome. ..
- African American Study of Kidney Disease and Hypertensi*Robert Toto; Fiscal Year: 2007..Such results might eventually lead to new strategies that delay or prevent ESRD. ..
- MENTORING PROGRAM FOR CLINICAL RESEARCHERS IN NEPHROLOGYRobert Toto; Fiscal Year: 2007....
- Pharmacogenetics of ACE inhibitor-associated angioedemaNancy Brown; Fiscal Year: 2009..In this way, this pharmacogenetic approach will provide new insight into the pathogenesis and prevention of this rare, but life-threatening, side effect of ACE inhibitors. ..
- GENES AND FIBRINOLYTIC CAPACITY OF HUMAN ENDOTHELIUMNancy Brown; Fiscal Year: 2006..It is expected that these pharmacogenetic studies will yield critical new information and strategies for enhancing the favorable effect of the kallikrein-kinin system on fibrinolysis and the risk of thrombotic cardiovascular events. ..
- TRAINING CURRICULUM IN PATIENT ORIENTED RESEARCHRobert Toto; Fiscal Year: 2004..The proposed program will provide young physicians and scientists with the skills needed to conduct clinical investigations and to compete for federal and non-federal research funding. ..
- Improving Outcomes in Diabetic NephropathyRobert Toto; Fiscal Year: 2003....
- GENES AND FIBRINOLYTIC CAPACITY OF HUMAN ENDOTHELIUMNancy Brown; Fiscal Year: 2002..This collaborative proposal provides a robust mechanism for highly focused translational research in the molecular genetics and biology of the role of the fibrinolytic system in arterial and cerebral thrombosis. ..
- Oxidized Linoleic Acid, Aldosterone, and ObesityTHEODORE GOODFRIEND; Fiscal Year: 2007..abstract_text> ..
- Human Cardiorenal SyndromeHorng Chen; Fiscal Year: 2009..This research should aid in addressing this health challenge. ..
- The Effect of Aldosterone on Cerebral Blood VesselsAnne Dorrance; Fiscal Year: 2007..These studies will elucidate a novel role for aldosterone in the pathogenesis of cerebrovascular disease, they will show that aldosterone not only increases EGFR density but also acts as a signaling molecule to enhance EGFR activation. ..
- Neurohormonal Blockade and Outcomes in Diastolic Heart FailureAli Ahmed; Fiscal Year: 2010..angiotensin-converting enzyme inhibitors (or angiotensin receptor blockers), beta-blockers and aldosterone antagonists, in three propensity-matched populations of Organized Program to Initiate Life-Saving Treatment in ..
- The Role of Vascular MR-Regulated Genes in Vascular Function and DiseaseIris Z Jaffe; Fiscal Year: 2010..abstract_text> ..
- Beta Cell Adaptation to Stress in Baboon Pancreas After Partial PancreatectomyFRANCO BATTISTA FOLLI; Fiscal Year: 2010....
- Mechanisms of Oxidative Stress and Inflammation during Prolonged Fasting and SleeRudy M Ortiz; Fiscal Year: 2010....
- HUMAN CARDIAC NA+ CHANNELS--EFFECTS OF PHOSPHORYLATIONKatherine Murray; Fiscal Year: 2000....
- Heart failure, chronic kidney disease, and renin-angiotensin system inhibitionAli Ahmed; Fiscal Year: 2009....
- G6PD AND OXIDANT STRESS IN VASCULAR SMOOTH MUSCLE CELLSJane Leopold; Fiscal Year: 2004..abstract_text> ..
- Mechanisms of Oxidative Stress and Inflammation during Prolonged Fasting and SleeRudy M Ortiz; Fiscal Year: 2010....
- Molecular Modulation of Cardiac Na+ Channel FunctionKatherine Murray; Fiscal Year: 2004..abstract_text> ..
- Fusion Proteins As Probes of P450 Structure and FunctionRichard Auchus; Fiscal Year: 2004..In addition, this approach might be generally applicable to structural studies of membrane-bound proteins. ..
- Aldosterone in angiotensin II-induced hypertensionRudy Ortiz; Fiscal Year: 2005..Unlike previous studies, the present study will provide a more comprehensive examination of the renal effects induced by aldo antagonism. ..
- MICROVASC OBSTRUCTION BY MRI AFTER CORONARY INTERVENTIONKatherine Wu; Fiscal Year: 2004..abstract_text> ..